Callio治疗技术公司获得1.87亿美元用于癌症药物开发,加强有针对性的治疗。 Callio Therapeutics secures $187M for cancer drug development, enhancing targeted treatments.

Callio治疗公司是一家新的生物技术公司,重点开发用于癌症治疗的多荷载抗体药物合体(ADCs),获得A系列1.87亿美元资金。 Callio Therapeutics, a new biotech company focused on developing multi-payload antibody-drug conjugates (ADCs) for cancer treatment, has secured $187 million in Series A funding. 这笔资金由Frazier生命科学牵头,将帮助扩大业务和推进其牵头方案,即HER2-目标两用双荷载ADC。 Led by Frazier Life Sciences, the funding will help expand operations and advance its lead program, a HER2-targeted dual-payload ADC. Callio还许可了蜂鸟生物科学ADC平台,以加强定向向肿瘤提供药物。 Callio also licensed Hummingbird Bioscience's ADC platform to enhance targeted drug delivery to tumors.